Kenya

'I saw it as a second chance': A qualitative exploration of experiences of treatment failure and regimen change among people living with HIV on second- and third-line antiretroviral therapy in Kenya, Malawi and Mozambique

Increasing numbers of people living with HIV (PLHIV) in sub-Saharan Africa are experiencing failure of first-line antiretroviral therapy and transitioning onto second-line regimens. However, there is a dearth of research on their treatment experiences. We conducted in-depth interviews with 43 PLHIV on second- or third-line antiretroviral therapy and 15 HIV health workers in Kenya, Malawi and Mozambique to explore patients' and health workers' perspectives on these transitions. Interviews were audio-recorded, transcribed and translated into English.

Include in home page features rotation
Off

Engaging study participants in interpreting results: Lessons from the TRIO study in Kenya and South Africa

Women account for 56% of new HIV infections in sub-Saharan Africa. Multipurpose Prevention Technologies (MPTs) are promising interventions because they combine HIV prevention with a less stigmatizing indication, such as pregnancy. We conducted a study with three placebo-only MPT products in Kisumu, Kenya and Soshanguve, South Africa, to assess preferences for attributes of tablets, vaginal rings and injectable products for dual prevention of HIV and pregnancy (TRIO Study). Here, we present former TRIO participants' views on the study results.
Include in home page features rotation
Off

Engaging study participants in interpreting results: lessons from the TRIO study in Kenya and South Africa

Background: Women account for 56% of new HIV infections in sub-Saharan Africa. Multipurpose Prevention Technologies (MPTs) are promising interventions because they combine HIV prevention with a less stigmatizing indication, such as pregnancy. We conducted a study with three placebo-only MPT products in Kisumu, Kenya and Soshanguve, South Africa, to assess preferences for attributes of tablets, vaginal rings and injectable products for dual prevention of HIV and pregnancy (TRIO Study). Here, we present former TRIO participants’ views on the study results.

Include in home page features rotation
Off

mothers2mothers (m2m) 2018 Evaluation

mothers2mothers (m2m) is an African NGO working towards the Global Goals of ensuring good health for all and ending the AIDS epidemic by 2030. The organization focuses on three core client groups—women, children, and adolescents—serving those living with HIV, and also those who are HIV-negative but at high risk of infection. m2m delivers services by training and employing local women living with HIV as Community Health Workers called Mentor Mothers.

Include in home page features rotation
Off

HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial

Injectable, intrauterine, and implantable contraceptives have been prioritised for programmatic delivery because of high contraceptive efficacy and safety. Robust evidence on the relative risks, particularly HIV susceptibility, and benefits of these contraceptive methods is important to inform women's decision making, provider counselling, and policy maker and regulatory decisions. Our primary objective was to compare HIV incidence among women using DMPA-IM, a copper IUD, or a levonorgestrel (LNG) implant.
Include in home page features rotation
Off

Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study

Author
Kathrin Zürcher, Marie Ballif, Prof Lukas Fenner, Sonia Borrell, Peter M Keller, Joachim Gnokoro et al.
Drug resistance is a challenge for the global control of tuberculosis. We examined mortality in patients with tuberculosis from high-burden countries, according to concordance or discordance of results from drug susceptibility testing done locally and in a reference laboratory.
Include in home page features rotation
Off

Plan 4 PrEP: Toolkit for oral PrEP implementation

Plan 4 PrEP is a set of unique tools that support national planning for oral PrEP rollout and scale-up based on OPTIONS’ technical experience. The toolkit includes six steps and corresponding worksheets on situation analysis, project landscape, rollout scenarios, district readiness assessment, facility readiness assessment, and private health sector landscape.

Legacy Evaluation of the Partnership for HIV-Free Survival: Kenya, Lesotho, Mozambique, South Africa, Tanzania, and Uganda

Author
David K. Hales, Heather B. Davis, Alexandra J. Munson, Emily A. Bobrow

The Partnership for HIV-Free Survival (PHFS) was designed to use basic quality improvement practices to reduce mother-to-child transmission of HIV and increase child survival through improvements in (1) antiretroviral therapy uptake and retention among HIV-positive pregnant women and mothers, (2) breastfeeding practices, and (3) overall mother-baby care. PHFS was implemented between 2012–2016 in six countries in Eastern and Southern Africa: Kenya, Lesotho, Mozambique, South Africa, Tanzania, and Uganda.

Include in home page features rotation
Off
Subscribe to Kenya